VCU HEART AND RENAL LAB AND TRANSPLANT TESTING

f specimens from Richmond VAMC, processing and analysis of the specimens, report of test results, and consultative services regarding specimen selection, collection, and result interpretation when needed. (see diagram) Contractor Responsibilities (a) Provide relevant testing information upon request for tests performed for our facility. (b) Provide storage of samples that may require future testing. (c) Analyze samples. The contractor shall return the test results to the VA laboratory within established timeframes via fax at 804-675-5518. (d) Contractor shall provide the VA laboratory with a means of communication to permit immediate inquiry regarding the status of pending test. (e) Contractor shall consult with the Richmond VAMC on test results by telephone when urgency of situation requires. (f) The Richmond VAMC laboratory reserves the right to request the results of any proficiency testing that the contractor subscribes to for testing performed for Richmond VAMC. (g) Contractor shall provide monthly invoices via Tungsten for tests provided by the 20th of each month following the month in which the service was delivered. (h) The testing laboratory will hold a valid CLIA certificate and maintain accreditation through a CMS-approved deemed status program, such as CAP, ASHI, COLA, or The Joint Commission. Documentation shall be provided to Richmond VAMC laboratory upon request. (i) The Contractor shall provide transportation/courier services to transport samples from Richmond VAMC to VCU HLA laboratory. Test Name CPT Codes Description LOW RESOLUTION TYPING: HLA Class I and Class II 81370 HLA-A,B,C, DRB1,DRB3/4/5, DQB1 FLOW CYTOMETRIC T&B Crossmatch 86825 HLA allo crossmatch-donor cell/ first serum sample HLA auto crossmatch � patient cell/patient serum ANTIBODY HLA CLASS I PHENOTYPE PANEL QUALITATIVE (WERFEN ID PANEL) 86830 Assessment of class I antibody using HLA phenotype panel ANTIBODY HLA CLASS II PHENOTYPE PANEL QUALITATIVE (WERFEN ID PANEL) 86831 Assessment of class II antibody using HLA phenotype panel ANTIBODY HLA CLASS I HIGH-DEFINITION PANEL QUAL (WERFEN SINGLE ANTIGEN BEAD PANEL, STANDARD TEST) 86832 Assessment of class I antibody to human leukocyte antigens (HLA) using high-definition panel ANTIBODY HLA CLASS II HIGH-DEFINITION PANEL QUAL (WERFEN SINGLE ANTIGEN BEAD PANEL, STANDARD TEST) 86833 Assessment of class II antibody to human leukocyte antigens (HLA) using high-definition panel ANGIOTENSIN II TYPE 1 ANTIBODY 86830 Assessment of AT1R antibody reactivity ANTIBODY HLA CLASS I SEMIQUANTITATE PANEL (ONE LAMBDA PANEL) 86834 Assessment of antibody to human leukocyte antigens (HLA), HLA class I supplemental panel ANTIBODY HLA CLASS II SEMIQUANTITATE PANEL (ONE LAMBDA PANEL) 86835 Assessment of antibody to human leukocyte antigens (HLA), HLA class II supplemental panel HIGH RESOLUTION HLA TYPING: HLA Class I and Class II (11 loci) 81378 + 81382 81378 includes HLA-A, B, C, DRB1. 81382 includes DQA1, DQB1, DRB3/4/5, DPA1, DPB1 LOW RESOLUTION TYPING: HLA Class II Only 81375 DRB1/3/4/5 and DQB1 FLOW CYTOMETRIC CROSSMATCH - Additional Serum 86826 HLA crossmatch each additional serum sample HLA Cell Cryopreservation 88240 Preparation of live cells for freezing and storage Interested sources shall indicate that they are capable of providing the required supply/services and must provide the following: 1) Full name and address of the firm 2) Size status (i.e., small business, 8(a), HUBZone, Service Disabled Veteran Owned small business 3) Offer item(s) on schedule or open market 4) Capability statement 5) NAICS Code 6) If small business, can your company meet the requirements specified in FAR 52.219-14, limitations on Subcontracting. Additional, at time of quote company must be registered in SAM.gov and if not the manufacturer provide a authorized distributor/licenser letter from the manufacture. No other information is required at this time. All respondents shall submit capability statements signifying that they meet the above-mentioned specifications. The capability statements received from this market research survey are for planning purposes only and will assist the Government in planning its acquisition strategy. This is strictly market research and the Government will not entertain questions concerning this market research survey. The Government will not assume any costs incurred by the contractor in the preparation of responses. All responses shall be submitted in the form of electronic mail no later than September 16, 2026 1pm, EST to the attention of: Gordon Burns, VA Medical Center, 27 Averill Avenue, Hampton, VA 23667. E-mail address:gordon.burns@va.gov. All responses shall contain the subject line; 36C24626Q1060 Lab Testing.